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Summary CA 15:3, a new tumour marker detectable by two monoclonal antibodies (115 D 8 and DF 3),
was measured by an immunoradiometric technique on the ELSA solid phase. Sixteen percent of patients with
localized breast cancer had CA 15:3 levels >25 U ml-1, and levels increased with tumour size. CA 15:3 levels
>25 Uml - were found in 54% of patients with nodal involvement and in 91% of patients with metastatic
breast disease. Measurement of CA 15:3 in 70 women with metastatic breast cancer and a normal CEA
revealed positive CA 15:3 levels at diagnosis of the first metastasis in 66% of cases; 63% of these patients
could be monitored with CA 15:3.
A simple, non-invasive means of investigation for the
diagnosis and follow-up of cancers which could be used for
selection of optimum therapeutic strategies would clearly be
desirable.
In malignant breast tumours, CEA has been the only
marker so far to partly satisfy the oncologists' requirements:
pre- and postoperative elevations of CEA carry a poor
prognosis (Wang et al., 1975), while a subsquent rise in CEA
is suggestive of metastasis (Tormey et al., 1975). However,
CEA is detectable in only one-third of cases when metastasis
is discovered (39% in our experience), and in three-quarters
of cases during the later course of disease (Namer et al.,
1985).
Recently, monoclonal antibodies have been generated
against a new tumour marker, CA 15:3, a high molecular
weight (290Kd) carbohydrate.
In an initial study, the reliability of this marker was
evaluated in a normal population and in patients with breast
carcinoma at various stages. To assess the prognostic value
of assays of this marker, tests were then conducted on a
group of patients with metastatic breast cancer whose CEA
level was negative when metastasis was diagnosed.
Patients and methods
CA 15:3 The commercial CA 15:3 radioimmunometric
assay (Oris Industrie S.A.) utilizes 2 monoclonal antibodies:
MAB 115 D 8, directed against antigens of human milk fat
globule membranes (Hilkens et al., 1983) and MAB DF 3,
directed against a membrane fraction of human breast cancer
(Kufe et al., 1984). CA 15:3 is measured by a solid phase
immunoradiometric system (ELSA tubes). The 115 D 8
antibody is coated on the ELSA solid phase; the DF 3
antibody, used as a tracer, is radiolabelled with iodine 125.
The average CA 15:3 level in normal adults (except in
pregnancy) is 13.7+5.2Uml-1 (mean+s.d.). The sensitivity
of the method is 0.2Uml-1. The threshold value was
arbitrarily set at 12.5Uml-1 (no extrapolation on the
calibration curve between 0 and 12.5). Intra-assay repro-
ducibilities and dilution tests were between 4.8 and 13.2%.
Inter-assay reproducibilities and dilution tests were between
12.9 and 14.5%.
Carcinombryonic antigen: CEA assays were performed with
the CEAK PR kit (Oris Industrie S.A.). The reagent is
polyclonal antiserum.
Patients
All patients were treated at the Centre A. Lacassagne (Nice,
France). Studies were performed retrospectively, using frozen
sera.
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CA 15:3 was investigated in two steps: in a preliminary
study, the validity of the tumour marker was evaluated and
its variations were analyzed at various stages of the disease.
A comparative study was then performed to determine
whether CA 15:3 offers any real advantages over CEA; a
population with negative CEA values was therefore included.
The preliminary study comprised 100 controls with no
malignant pathology; and 179 patients with breast cancer,
classified by the TNM system (tumour size, nodal
involvement, and presence of metastasis): 85 patients N-
(classed by tumour size), 39 patients N+ and 55 patients
M+.
The comparative study involved 152 patients with
metastatic breast cancer: 82 patients with metastatic breast
cancer and an abnormal CEA level: and 70 patients with
metastatic breast cancer whose CEA level always remained
in the normal range.
Results
Preliminary study
Only one of the 100 controls (patients without any malignant
pathology) had a CA 15:3 level >25Uml-.
The 85 breast cancer patients without nodal involvement
and without metastasis were classified according to tumour
size. In this population, the incidence of CA 15:3 levels
>25Uml-1 was 9% (3/32) for TI, 18% (7/38) for T2, and
27% (4/15) for T3+T4N-. The overall incidence of CA
15:3 values >25Uml-1 in the 85 breast cancer patients
without nodal involvement was 14/85 (16%). By contrast,
54% (21/39) of patients with nodal involvement presented
with CA 15:3 levels >25Uml-'. Fifty of the 55 patients
(91%) with metastatic breast cancer had a CA 15:3 level
>25Uml-'(Figure 1).
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Figure 1 CA 15:3 concentrations for controls and TNM classes
of breast cancer patients.
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In view of these results, a larger population of patients
with metastatic breast cancers was investigated, and CEA
levels were compared with CA 15:3 concentrations.
Comparative study
In order to compare CA 15:3 with CEA, 152 patients were
studied at the time their first metastasis was discovered.
Seventy-nine of 82 patients with CEA levels between 10
and 500ngml-1 (96%) had a CA 15:3 level >25Uml-P
(upper limit 18,000Uml-1). There was no correlation
(r=0.032) between CA 15:3 and CEA levels. (Figure 2).
Forty-six of 70 patients (66%) with a CEA level in the
normal range at diagnosis of their first metastasis had a CA
15:3 level >25Uml-1 and 24 patients had a concentration
<25Uml-1. This group was analyzed to assess CA 15:3 in
a CEA negative population.
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Figure 2 Distribution of values: simultaneous
15: 3 measurement.
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CEA and CA
Metastatic sites as a function of the CA 15:3 level Sites of
metastasis at the time of their first clinical manifestation
were studied in the CEA-negative metastatic breast cancer
group, as a function of their CA 15:3 value. The Mann-
Whitney statistical test revealed a significant difference
(P<0.001) between multiple and single sites of metastasis in
relation to CA 15:3 levels. In the subgroup with a solitary
metastasis, a significant difference was noted between bone
and skin sites (P<0.01); no difference was seen between
bone and pulmonary metastases (Table I).
Relationship between clinical and biological variation To
evaluate the usefulness of CA 15:3 in the group with CEA
<5ngml-1, variations in CA 15:3 were studied with respect
to clinical findings. The patients selected for study had
simultaneous disease evaluation and a CA 15:3 assay.
Disease evaluation was based on physical examination,
standard chest X-rays and lung tomography in cases of
pulmonary metastasis, scintiscanner and/or films centred on
high uptake foci in cases of bone metastasis, photographs of
lesions in cases of skin metastasis and liver sonograms for
liver metastasis. Clinical observations were used to determine
the objective response as defined by WHO criteria (Miller et
al., 1981), modified by the introduction of minimal response
(MR) corresponding to a 25-50% decrease in total tumour
size determined by two observations not less than 4 weeks
apart.
CA 15:3 was measured at the same time as the physical
examination; only a 20% difference between two CA 15:3
levels was taken into account. A difference of <20% was
considered as showing no variation in the marker. (Figure 3).
Using these criteria, a total of 100 clinical and biological
correlations were available for analysis: in 29 cases, either
the physical examination or the biological level of CA 15:3
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Table I Distribution of metastatic sites as a function of
CA 15:3 levels. (Mann-Whitney test). Except for skin
versus bone, elevations in CA 15:3 were systematically
lower for solitary metastases, regardless of the site
Comparison of Median (and range)
metastatic sites ofCA 15:3 Uml- t P
12 Skin 25 (<25,68)
versus 0.81 NS
16 Pulmonary 30 (<25,178)
12 Skin 25 (<25,68)
versus 3.04 <0.01
19 Bone 45 (<25,3100)
12 Skin 25 (<25,68)
versus 4.06 <0.01
14 Multiple 93 (<25,860)
16 Pulmonary 30 (<25,178)
versus 0.76 NS
19 Bone 45 (<25, 3100)
16 Pulmonary 30 (<25,178)
versus 3.10 <0.01
14 Multiple 93 (<25,860)
19 Bone 45 (<25,3100)
versus 1.71 NS
14 Multiple 93 (<25,860)
47 Solitary 35 (<25,3100)
versus 5.70 <0.001
14 Multiple 93 (<25,860)
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Figure 3 Value of CA 15:3 in a patient whose CEA was always
<5ngml 1. The patient presented in February 1981 (1) with an
adenocarcinoma of the right breast (T3, NO, MO), treated by 3
courses of induction chemotherapy. A mastectomy with axillary
dissection was performed in June 1981 (2), followed by 9 courses
of chemotherapy (3 to 4). In September 1983 (5), hyperactive foci
appeared on scintiscans although X-rays remained negative.
Confirmation of bone metastasis was obtained in July 1984 (6),
when hormone therapy was instituted with tamoxifen. In
December 1984 (7), the number of bone foci on scintiscans had
decreased, and zones of recalcification were observed on centred
X-ray films.
did not change; in view of the ambiguity of these cases, they
have not been included in the analysis.
Sixty-three good correlations: Comparison of the two
situations revealed either an objective complete response
(CR), partial response (PR) or minimal response (MR) with
a significant decrease in CA 15:3, or progressive disease
(PD) associated with a significant increase in CA 15:3.
Eight poor correlations: the comparison of the two
situations revealed either CR, PR or MR with a significant
increase in CA 15:3 or PD associated with a significant
decrease in CA 15:3 (3 cases).
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Predictive value Nine of 48 patients with a CA 15:3 level
>25Uml-' and a CEA level <5ngml-P, at the time that
their first metastasis was detected, had had an assay
performed over 6 months previously: 6 were >25Uml-1,
even though there were no clinical signs of metastasis.
Discussion
Preliminary study
CA 15:3 is a good tumour marker because only one control
in 100 had an abnormal CA 15:3 level.
Various authors (Ballesta et al., 1985; Tobias et al., 1985)
have set the significant threshold value between 30 and
50Uml-1 to avoid overestimation due to false positives. In
breast cancer follow-up, the main problem is detection of
local recurrence or distant metastasis; as false negatives must
be avoided in these cases, we recommend a threshold value
of 25Uml-1.
Analysis of CA 15:3 levels >25 Uml-1 according to
tumour size revealed an increase in the prevalence of
elevated values with increasing tumour size (Namer et al.,
1985; Bolla et al., 1983) are comparable to those for CA
15:3. The incidence of CA 15:3 levels >25Uml-1 in the
N- group was 16% and 54% in the N+ group. The
sensitivity is higher than the overall incidence of elevated
CEA values (>5ngml-1) found during one of our previous
studies: 7 positive CEA values in N- tumors versus 11% in
N+. CA 15:3 was more sensitive than CEA at the time of
diagnosis of non-metastatic breast cancer.
Comparative study
In metastatic breast cancer, high CA 15:3 levels were noted
in 96% of patients with a positive CEA level versus only
66% of patients who were CEA-negative. The incidence of
elevated CA 15:3 levels was 82% (125/152) when the CEA
value was not taken into consideration. The presence of
metastasis does not always imply a rise in CA 15:3.
Simultaneous measurement of CA 15:3 and CEA allowed
monitoring of 128 (82 CEA-positive patients; 46 CA 15:3-
positive and CEA-negative patients) out of 152 with breast
cancer; 84% had at least one positive marker at diagnosis of
metastasis.
Investigations concerning metastatic sites as a function of
CA 15:3 levels gave findings similar to studies with CEA
(Namer et al., 1978). CA 15:3 levels in patients with multiple
metastases were significantly higher than those in patients
with a solitary metastasis. Other comparisons by metastatic
site involved too few cases to allow any definite conclusions.
CEA, a marker commonly used for the follow-up of
patients with breast cancer, allowed monitoring of two-thirds
of patients (Namer et al., 1978). The problem with CEA,
however, is the fact that it is not often abnormal (only 39%
of cases in our series). CA 15:3 was elevated in 66% of the
population with a normal CEA level. For these patients, CA
15:3 allowed effective monitoring in two-thirds of cases; a
greater frequency of elevated values means that information
is available for a larger number of patients: this was the case
for CA 15:3.
Furthermore, 6 of the 9 assays performed during the 6
months preceding the appearance of metastasis were
>25 Uml-1 even though metastasis was not clinically
evident. This suggests that repeat CA 15:3 measurements
during the follow-up of patients with no evidence of disease
allows metastasis to be predicted before clinical
manifestations occur.
In conclusion, CA 15:3 is more sensitive than CEA when
the primary tumour is diagnosed and when metastasis is
discovered. In this last situation, it allowed monitoring in
two-thirds of the cases. CA 15:3 levels were elevated more
frequently than CEA levels, and CA 15:3 thus appears a
superior marker than CEA in breast cancer prognosis.
The authors wish to thank A. Galland, C. Rossi and A. Jourlait for
technical assistance, N. Defabri for secretarial assistance, N.
Rameau for assistance with the translation, and M.L. Vella for
statistical analysis.
References
BALLESTA, A.M., MOLINA, R., MARIN, J.L. & 4 others (1985). A
new tumor marker CA 15:3 defined by monoclonal antibodies.
Initial clinical evaluation in patients with breast cancer. Proc.
XIII Annual Meeting ISOBM, Paris (Abstract).
BOLLA, M., DAIDJ, H., LACHET, B., BOUCHET, Y. & VROUSOS, C.
(1983). L'antigene carcinoembryonnaire dans le tumeurs du sein:
Evaluation initiale et surveillance. Bull. Cancer, 70, 300.
HILKENS, J., HILGERS, J., BUIJS, F. & 4 others (1983). Monoclonal
antibodies against human milkfat globule membranes useful in
carcinoma research. Prot. Biol. Fluids, 31, 1013.
KUFE, D., INGHIRAMI, G., ABE, M., HAYES, D., JUSTIWHEELER, H.
& SCHOLM, J. (1984). Differential reactivity of a novel
monoclonal antibody (DF3) with human malignant versus
benign breast tumors. Hybridoma, 3, 223.
MILLER, A.B., HOOGSTRATEN, B., STAQUET, M. & WINKLER, A.
(1981). Reporting results ofcancer treatment. Cancer, 47, 207.
NAMER, M., HERY, M., ABBES, M. & 5 others (1978). Interest of
carcinoembryonic antigen in the follow-up and treatment of
breast cancer. In Clinical Application of Carcinoembryonic
Antigen. KREBS, et al. (eds), p. 225. Excerpta Medica,
Amsterdam.
NAMER, M., KREBS, B.P., RAMEAU, Ph., HERY, M. & PHILIP, C.
(1985). Les marqueurs tumoraux dans le cancer du sein:
Comment les utiliser en 1985? In Les maladies du sein en 1985:
Formation medicale continue en Senologie. 7 eme journee de la
Soci&te Frangaise de Senologie et Pathologie Mammaire,
Demaille (ed.) p. 20.
TOBIAS, R., ROTHWELL, C., WAGNER, J., GREEN, A. & V.LIU, Y.S.
(1985). Development and evaluation of a radioimmunoassay for
the detection of a monoclonal antibody defined breast tumor
associated antigen 115D8/DF3. Clin. Chem., 31, 986.
TORMEY, D.C., WAALKES, T.P., AHMANN, D. & 4 others (1975).
Biological markers in breast carcinoma. Incidence of abnormal-
ities of CEA, hCG, three polyamines and three minor
nucleosides. Cancer, 35, 1095.
WANG, D.Y., BULBROOK, R.D., HAYWARD, J.L., HENDRICK, J.C. &
FRANCHIMONT, P. (1975). Relationship between plasma carcino-
embryonic antigen and prognosis in women with breast cancer.
Eur. J. Cancer, 11, 615.